DataVXACS Applied Nano MaterialsPaper
journal article·2022-01-28

Co-delivery of Chemotherapeutic Drugs and Immune Adjuvants by Nanoscale DNA Tetrahedrons for Synergistic Cancer Therapy

Qian Wang, Yuxuan Ma, Zhangwei Lu, Hanyang Yu, Zhe Li

ACS Applied Nano Materials· Volume 5· Issue 1
Publisher page
Source abstract

Abstract

Chemoimmunotherapy represents an attractive approach for cancer treatment, which requires a compatible co-delivery system to achieve the synergetic therapeutic effects. Among various nanocarriers, DNA nanostructures have recently been proposed as promising candidates for drug delivery system due to the excellent biocompatibility. Herein, we employ DNA tetrahedron to create a co-delivery nanoplatform that combines the chemotherapeutic drug doxorubicin and the immunotherapeutic agent CpG oligodeoxynucleotides. The DTN-CpG/DOX nanoparticles show synergistic therapeutic effects in terms of enhanced immunostimulatory activity and pronounced antitumor efficiency. The simultaneous loading drugs with modifiable DNA nanostructures represent an attractive strategy for facile delivery of various therapeutic components.
Source: openalex_inverted_index · Quality: baseline

Research context

NanomaterialsBiomaterials

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, Jiangsu 210023, China

State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, Jiangsu 210023, China

State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, Jiangsu 210023, China

Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, Jiangsu 210023, China

Funding

Ministry of Science and Technology of the People's Republic of China · Central University Basic Research Fund of China · Government of Jiangsu Province · National Natural Science Foundation of China

References (30)

Show source-provided references
1. 10.1158/0008-5472.CAN-07-661110.1158/0008-5472.CAN-07-6611 ↗
2. 10.1016/0277-5379(83)90418-210.1016/0277-5379(83)90418-2 ↗
3. 10.18632/oncotarget.1672310.18632/oncotarget.16723 ↗
4. 10.1039/C4BM00369A10.1039/C4BM00369A ↗
5. 10.3390/molecules2406103510.3390/molecules24061035 ↗
6. 10.1016/j.biomaterials.2011.10.05710.1016/j.biomaterials.2011.10.057 ↗
7. 10.1002/smll.20090062110.1002/smll.200900621 ↗
8. 10.1016/j.biomaterials.2011.10.03510.1016/j.biomaterials.2011.10.035 ↗
9. 10.1002/smll.20130188510.1002/smll.201301885 ↗
10. 10.1146/annurev-med-040210-16254410.1146/annurev-med-040210-162544 ↗
11. 10.1007/s12274-018-2152-310.1007/s12274-018-2152-3 ↗
12. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
13. 10.1021/nn502058j10.1021/nn502058j ↗
14. 10.1021/ja304263n10.1021/ja304263n ↗
15. 10.1038/nbt.407110.1038/nbt.4071 ↗
16. 10.1002/anie.20190934510.1002/anie.201909345 ↗
17. 10.1002/anie.20180945210.1002/anie.201809452 ↗
18. 10.1002/adma.20150631210.1002/adma.201506312 ↗
19. 10.1021/acsnano.0c0613610.1021/acsnano.0c06136 ↗
20. 10.1016/j.chempr.2018.02.00510.1016/j.chempr.2018.02.005 ↗
21. 10.1039/D1NR00197C10.1039/D1NR00197C ↗
22. 10.1038/onc.2010.43710.1038/onc.2010.437 ↗
23. 10.1016/j.ijbiomac.2014.02.02810.1016/j.ijbiomac.2014.02.028 ↗
24. 10.1016/j.talanta.2017.11.03410.1016/j.talanta.2017.11.034 ↗
25. 10.1016/j.uct.2007.11.00310.1016/j.uct.2007.11.003 ↗
26. 10.1016/j.addr.2008.12.00810.1016/j.addr.2008.12.008 ↗
27. 10.18388/abp.2006_337910.18388/abp.2006_3379 ↗
28. 10.1021/nn202774x10.1021/nn202774x ↗
29. 10.1039/C7NR04396A10.1039/C7NR04396A ↗
30. 10.1001/jamaoncol.2017.018410.1001/jamaoncol.2017.0184 ↗